Pharmacogenomics: Post-Drug Development

Pharmacogenomics: Post-Drug Development

Pharmacogenomics: Post-Drug Development Pharmacogenomics is the study of genes and how they impact drug response in certain individuals. This information allows physicians to customize treatment plans for their patients by taking into account a patient’s genetic...
Pharmacogenomics Financing

Pharmacogenomics Financing

Pharmacogenomics is the study of how genes affect drug responses in patients. Because pharmacogenomics is still in its infancy and U.S. healthcare systems have not yet adopted it, the financial burden often falls to patients to pay for genomic testing. However, as...
Pharmacogenomics: Changes in Drug Development

Pharmacogenomics: Changes in Drug Development

Pharmacogenomics: Changes in Drug Development Pharmacogenomics is the study of how genes affect a person’s response to drugs.  As the field grows, it holds many implications for the future of drug development.  Pharmaceutical companies are now rethinking the drug...
Is Chinese CRISPR Experiment on Babies Ethically Justified?

Is Chinese CRISPR Experiment on Babies Ethically Justified?

Chinese scientist He Jiankui’s decision to genetically modify newborns using CRISPR technology has drawn harsh criticism from the scientific community.  Jiankui’s decision to edit the genomes was motivated by a desire to prevent future disease and other potential...
Why Patients Aren’t Joining Your Clinical Trial (Part 2)

Why Patients Aren’t Joining Your Clinical Trial (Part 2)

This is part 2 of a 2 part series on patient centricity in clinical trials.  You can read part 1 here. In this follow-up to our recent discussion on clinical trial enrollment, we will discuss how an emphasis on patient centricity will help clinical trial researchers...

Why Patients Aren’t Joining Your Clinical Trial (Part 1)

Show Transcript Major:              Hey guys my name’s Major, I’m here with Darshan, and today we’re talking about why patients are not joining your clinical trial. Darshan.Darshan:            So it’s been good to get back to this. It’s...